Rotterdam

• Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended recruitment
  2023-504471-25-00 5 2024-03-01 Fibrotic Lung Disease
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended recruitment
  2023-503827-25-01 5 2024-02-16 Non-Small Cell Lung Cancer (NSCLC)
• ViaskinTM Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy (VITESSE) Ended recruitment
  2022-502110-85-00 5 2024-01-18 Peanut allergy
• Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended recruitment
  2023-504553-12-01 6 2023-12-27 Influenza
• ETOP 14-18 CHESS: Immunotherapy, chemotherapy and radiotherapy, followed by surgery or radiotherapy, for patients with newly diagnosed non-s … Ended recruitment
  2024-511134-12-00 4 2023-12-20 NSCLC, synchronous oligo-metastatic
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended recruitment
  2022-502669-14-00 5 2023-12-18 Small cell lung cancer (SCLC)
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cell … Ended recruitment
  2022-500782-27-00 7 2023-11-14 relapsed/refractory Multiple Myeloma
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib in G12C NSCLC Patients (RAMP203) Ended recruitment
  2023-505107-24-00 9 2023-11-14 Non-small cell lung cancer
• A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended recruitment
  2022-503004-24-00 5 2023-10-20 Influenza virus
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate … Ended recruitment
  2022-502188-39-00 4 2023-09-27 Dermatitis atopic
• Safe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: a randomized controlled … Ended recruitment
  2023-504817-56-00 6 2023-09-05 Bronchiolitis
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority ran … Ended recruitment
  2023-504171-24-00 6 2023-08-14 Atopic eczema
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) Ended recruitment
  2024-512580-31-00 5 2023-07-21 Kidney Transplant Rejection
• HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation … Ended recruitment
  2022-502225-17-00 4 2023-07-14 Hodgkin lymphoma
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation and a non-comparative transplante … Ended recruitment
  2022-502727-21-00 5 2023-07-03 Highly sensitised patients who have undergone kidney transplantation a
• A research study looking at how safe somapacitan is and how well it works in children who need help to grow – REAL 9 Ended recruitment
  2022-501055-87-01 5 2023-05-18 Noonan syndrome
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended recruitment
  2022-501463-40-01 5 2023-05-03 Locally Advanced or Metastatic Cholangiocarcinoma

Showing 505–528 of 818 trials